Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
This program assesses the laboratory’s ability to detect c-Myc and Bcl-2-positivity in large B-cell lymphomas, which have emerged as critical prognostic markers.
- Two 10‑core tissue microarray slides, one for c-Myc and one for Bcl-2
Shipment A: April 12
Shipment B: October 11